Dr. Brian Barry, M.D
NPI: 1013335165
Total Payments
$332,321
2024 Payments
$52,268
Companies
15
Transactions
199
Medicare Patients
1,598
Medicare Billing
$222,209
Payment Breakdown by Category
Other$291,447 (87.7%)
Consulting$26,870 (8.1%)
Travel$8,629 (2.6%)
Food & Beverage$5,346 (1.6%)
Education$29.76 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Grant | $257,800 | 3 | 77.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $32,647 | 12 | 9.8% |
| Consulting Fee | $26,870 | 11 | 8.1% |
| Travel and Lodging | $8,629 | 17 | 2.6% |
| Food and Beverage | $5,346 | 153 | 1.6% |
| Honoraria | $1,000 | 1 | 0.3% |
| Education | $29.76 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $258,081 | 6 | $0 (2022) |
| TG Therapeutics, Inc. | $29,453 | 23 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $16,651 | 17 | $0 (2024) |
| Genentech USA, Inc. | $8,812 | 23 | $0 (2024) |
| Celgene Corporation | $8,279 | 29 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $6,693 | 32 | $0 (2024) |
| EMD Serono, Inc. | $1,904 | 6 | $0 (2023) |
| Horizon Therapeutics plc | $1,591 | 32 | $0 (2023) |
| Amgen Inc. | $322.74 | 14 | $0 (2024) |
| GENZYME CORPORATION | $219.28 | 10 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $52,268 | 102 | TG Therapeutics, Inc. ($23,197) |
| 2023 | $12,138 | 47 | TG THERAPEUTICS, INC. ($6,255) |
| 2022 | $6,447 | 32 | Novartis Pharmaceuticals Corporation ($5,775) |
| 2021 | $1,102 | 5 | Horizon Therapeutics plc ($1,047) |
| 2020 | $92,133 | 5 | Biogen, Inc. ($89,900) |
| 2019 | $90,129 | 5 | Biogen, Inc. ($90,021) |
| 2018 | $78,103 | 3 | Biogen, Inc. ($78,083) |
All Payment Transactions
199 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Celgene Corporation | ZEPOSIA (Drug) | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: Neuroscience | ||||||
| 12/19/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $28.34 | General |
| Category: Neurology | ||||||
| 12/11/2024 | Genentech USA, Inc. | Ocrevus (Biological), Ocrevus Zunovo | Food and Beverage | In-kind items and services | $35.79 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $7.17 | General |
| Category: Neurology | ||||||
| 12/09/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,240.00 | General |
| Category: Neuroscience | ||||||
| 12/09/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,404.00 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $699.15 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $212.19 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $50.12 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $50.12 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $31.39 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $26.54 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $26.54 | General |
| Category: Neuroscience | ||||||
| 12/05/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $3.01 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/02/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $990.00 | General |
| 11/21/2024 | Genentech, Inc. | Ocrevus (Biological) | Food and Beverage | In-kind items and services | $118.45 | General |
| Category: Immunology | ||||||
| 11/07/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $2,449.53 | General |
| Category: Neuroscience | ||||||
| 11/07/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $274.30 | General |
| Category: Neuroscience | ||||||
| 11/07/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $72.20 | General |
| Category: Neuroscience | ||||||
| 11/07/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $23.87 | General |
| Category: Neuroscience | ||||||
| 10/25/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $7.27 | General |
| Category: Neurology | ||||||
| 10/21/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,107.50 | General |
| Category: Immunology | ||||||
| 10/21/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $28.69 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/21/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $28.13 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/21/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $1.03 | General |
| Category: Inflammation/Rare Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 424 | 499 | $187,235 | $65,265 |
| 2022 | 8 | 460 | 544 | $176,402 | $63,885 |
| 2021 | 8 | 535 | 651 | $192,363 | $72,312 |
| 2020 | 8 | 179 | 196 | $57,343 | $20,748 |
Total Patients
1,598
Total Services
1,890
Medicare Billing
$222,209
Procedure Codes
41
All Medicare Procedures & Services
41 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 68 | 84 | $33,479 | $11,917 | 35.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 90 | 109 | $31,969 | $11,784 | 36.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 70 | 70 | $28,433 | $9,907 | 34.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 54 | 54 | $26,244 | $7,740 | 29.5% |
| 99483 | Assessment of and care planning for patient with impaired thought processing, typically 60 minutes | Office | 2023 | 23 | 28 | $19,320 | $6,964 | 36.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 36 | 55 | $14,712 | $5,695 | 38.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 36 | 50 | $9,208 | $3,523 | 38.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 16 | 18 | $11,052 | $3,223 | 29.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 14 | 14 | $7,242 | $2,606 | 36.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 17 | 17 | $5,576 | $1,906 | 34.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 98 | 143 | $37,857 | $14,541 | 38.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 68 | 69 | $33,534 | $11,493 | 34.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 61 | 68 | $24,004 | $10,383 | 43.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 56 | 56 | $22,456 | $7,498 | 33.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 44 | 67 | $16,750 | $5,853 | 34.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 21 | 21 | $10,563 | $3,844 | 36.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 44 | 45 | $11,295 | $3,435 | 30.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 19 | 19 | $6,270 | $2,088 | 33.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 25 | 31 | $5,363 | $1,910 | 35.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 13 | 14 | $4,592 | $1,670 | 36.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 11 | 11 | $3,718 | $1,170 | 31.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 113 | 180 | $47,340 | $20,785 | 43.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 64 | 65 | $31,590 | $11,105 | 35.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 73 | 73 | $29,273 | $9,766 | 33.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 51 | 58 | $20,474 | $8,320 | 40.6% |
About Dr. Brian Barry, M.D
Dr. Brian Barry, M.D is a Student in an Organized Health Care Education/Training Program healthcare provider based in Washington, District of Columbia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/04/2014. The National Provider Identifier (NPI) number assigned to this provider is 1013335165.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Brian Barry, M.D has received a total of $332,321 in payments from pharmaceutical and medical device companies, with $52,268 received in 2024. These payments were reported across 199 transactions from 15 companies. The most common payment nature is "Grant" ($257,800).
As a Medicare-enrolled provider, Barry has provided services to 1,598 Medicare beneficiaries, totaling 1,890 services with total Medicare billing of $222,209. Data is available for 4 years (2020–2023), covering 41 distinct procedure/service records.
Ad
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Other Specialties Neurology
- Location Washington, DC
- Active Since 04/04/2014
- Last Updated 08/26/2020
- Taxonomy Code 390200000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1013335165
Products in Payments
- BRIUMVI (Drug) $29,453
- ZEPOSIA (Drug) $23,322
- Ocrevus (Biological) $6,757
- KESIMPTA (Drug) $6,693
- OCREVUS (Biological) $2,251
- UPLIZNA (Drug) $1,591
- UPLIZNA (Biological) $322.74
- Mavenclad (Biological) $73.24
- AUBAGIO (Drug) $59.85
- RYTARY (Drug) $42.67
- QULIPTA (Drug) $40.46
- Ocrevus Zunovo (Biological) $22.79
- Evobrutinib $12.34
- BOTOX (Biological) $12.29
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in Washington
Kathryn Sowerwine
Student in an Organized Health Care Education/Training Program — Payments: $833,607
Student in an Organized Health Care Education/Training Program $833,607
Dr. Benjamin Weinberg, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $283,071
Student in an Organized Health Care Education/Training Program $283,071
Joshua Reuss, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $180,362
Student in an Organized Health Care Education/Training Program $180,362
Chul Kim
Student in an Organized Health Care Education/Training Program — Payments: $109,637
Student in an Organized Health Care Education/Training Program $109,637
Dr. Yana Najjar, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $97,869
Student in an Organized Health Care Education/Training Program $97,869
Dr. Ashley Broussard, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $96,211
Student in an Organized Health Care Education/Training Program $96,211